

IOLCP/CGC/2023 9th November 2023

National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Security Symbol: IOLCP BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai- 400 001 Security Code: 524164

Subject: Investor Presentation – Q2 & H1 FY24.

Dear Sir,

Please find enclosed herewith Investor Presentation on the Financial Results of the Company for the quarter and half year ended 30th September 2023.

This presentation is being submitted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended.

This presentation is also made available on the Company's website www.iolcp.com

This is for your information and records.

Thanking You,

Yours faithfully, For IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh Sr. Vice President & Company Secretary

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Punjab) India CIN - L24116PB1986PLC007030 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com Regd. Office : Village & Post Office Handiaya, Fatehgarh Channa Road, Barnala-148107, Punjab, India. Works : Village Fatehgarh Channa, Mansa Road (Trident Complex) District - Barnala, 148101 State - Punjab, India. Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



IOL Chemicals and Pharmaceuticals Limited Q2 & H1 FY24 Investor Presentation November 2023





IOL Chemicals And Pharmaceuticals Limited

This presentation has been prepared by IOL Chemicals & Pharmaceuticals Limited (the "Companies", IOL) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the companies will be made except by means of a statutory offering document containing detailed information about the Companies.

This Presentation has been prepared by the Companies based on information and data which the Companies considers reliable, but the Companies makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the companies market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the companies ability to successfully implement its strategy, the companies future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the companies market preferences and its exposure to market risks, as well as other risks. The companies actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The companies assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the companies and the companies is not responsible for such third party statements and projections.

Table of Contents

IOL Chemicals And Pharmaceuticals Limited

01 IOLCP at a glance

- About IOL Chemicals and Pharmaceuticals Ltd.
- Q2FY24 & H1-FY24 Performance
- Geographical & Segmental Highlights

02 Financial Highlights

- Quarterly & Half-yearly Income Statement
- Growing top-line
- Building Assets
- Cash Flow Statement
- 5 years performance highlights
- Diversified Revenue base

03 Company Overview

- The Journey
- Core management team
- Board of Directors
- Certification & Accreditation

04 Business Overview

- Pharmaceutical-Building API Portfolio
- Specialty Chemicals-Capitalizing on global demand
- Manufacturing Facilities
- Ensuring a Sustainable Tomorrow Through ESG Initiatives

05 Industry Overview

- Pharmaceutical-Emerging strongly out of pandemic
- Chemical Sector- An era of sustained robust growth

06 Way Forward

- Charting a path to success
- Expanding the non-Ibuprofen business
- Summary



Incorporated in 1986, IOLCP is one of the leading API Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities







Q2FY2	<mark>4 Financial P</mark>	Performance	
552.41 Revenues (Rs. cr)			 Reduction in raw material cost YoY leads to better EBITDA and Net Profit margins Pharma revenue grows nearly 10% leading to overall sales
37.79 Profit After (Rs. cr)	Tax	6.8% PAT Margin	 growth Chemical revenue flattish in second quarter





Geographical and Segmental highlights

- IOL Chemicals And Pharmaceuticals Limited









FINANCIAL HIGHLIGHTS

Quarterly & Half yearly Income Statement



Particulars (Rs. Cr)	Q2 FY24	Q2 FY23	YoY	Q1 FY24	H1 FY24	H1 FY23	YoY
Revenues	545.3	541.4	0.7%	563.2	1108.5	1,106.4	0.2%
Other Income	7.1	5.1		7.1	14.2	10.2	
Total Income	552.4	546.5	1.1%	570.3	1122.7	1,116.6	0.5%
Total Expenses	481.2	509.7		490.4	971.6	1,018.7	
EBITDA	71.2	36.7	93.5%	79.9	151.1	97.9	54.4%
EBITDA Margin (%)	12.9%	6.7%	620bps	14.0%	13.5%	8.8%	470 bps
Depreciation	15.7	11.32		14.4	30.1	22.3	
Finance Cost	4.4	3.51		4.0	8.4	6.9	
Profit Before Exceptional Items	51.1	21.90	132.3%	61.5	112.6	68.7	64%
Exceptional items (Expense) / Income							
Profit Before Tax	51.1	21.90		61.5	112.6	68.7	
Tax	13.3	6.23		15.3	28.6	18.2	
Profit After Tax	37.8	15.67		46.2	84.0	50.56	
PAT Margin (%)	6.8%	2.9%	390bps	8.1%	7.5%	4.5%	300bps
Other Comprehensive Income	-0.5	-0.3		-1.2	-1.7	-0.8	
Total Comprehensive Income	37.3	15.3		45.0	82.3	49.8	
Basic & Diluted EPS (INR)	6.4	2.7		7.9	14.3	8.6	

8

Growing top-line



Particulars (Rs. Cr)	FY19	FY20	FY21	FY22	FY23	H1-FY24
Revenues	1,685.3	1,894.5	1,967.0	2,184.0	2,217.1	1108.5
Other Income	10.4	16.0	24.3	32.0	25.6	14.2
Total Income	1,695.7	1,910.5	1,991.3	2,216.0	2,242.7	1122.7
Total Expenses	1,275.7	1,320.6	1,375.2	1,927.6	1,990.6	971.6
EBITDA	420.0	589.9	616.1	288.4	252.1	151.1
EBITDA Margin (%)	24.8%	30.9%	30.9%	13.0%	11.2%	13.5%
Depreciation	32.5	35.7	38.9	43.3	46.1	30.1
Finance Cost	51.4	20.9	5.8	8.3	16.5	8.4
Profit Before Exceptional Items	336.1	533.3	571.4	236.8	189.5	112.6
Exceptional items (Expense) / Income				-13.9		
Profit Before Tax	336.1	533.3	571.4	222.9	189.5	112.6
Tax	99.5	172	126.8	57.2	49.5	28.6
Profit After Tax	236.6	361.3	444.6	165.7	140.0	84.0
PAT Margin (%)	14.0%	18.9%	22.3%	7.5%	6.2%	7.5%
Other Comprehensive Income	-1.4	-1.52	-2.14	-0.6	-0.2	-1.7
Total Comprehensive Income	235.2	359.8	442.5	165.1	139.8	82.3
Basic & Diluted EPS (INR)	42.1	63.4	76.2	28.2	23.8	14.3





Balance Sheet (Rs. Cr)	FY19	FY20	FY21	FY22	FY23	H1-FY24
Shareholders' Funds	474.3	813.5	1260.4	1390.3	1506.6	1588.8
Debt	284.0	56.0	0.0	0.0	0.0	0.0
Total Non-current Liabilities	20.8	79.7	59.1	56.6	58.1	61.5
Total Current Liabilities	162.8	220.6	290.6	513.4	455.9	429.9
Equity & Liabilities	941.9	1169.8	1610.1	1960.3	2020.6	2080.2
Fixed Assets	438.7	488.2	560.6	665.8	841.0	894.5
Fixed Deposits (Non-Current)	6.9	5.3	21.2	203.7	230.7	203.7
Other Non-Current Assets	8.3	5.4	6.0	12.0	29.8	63.6
Non Current Assets	453.8	498.9	587.8	881.5	1101.5	1161.8
Investments	0.1	0.1	1.2	2.4	2.6	2.7
Cash & Bank Balances	29.6	154.7	364.8	137.9	20.9	58.4
Other Current Assets	458.4	516.1	656.3	938.5	895.6	857.3
Current Assets	488.1	670.9	1022.3	1078.8	919.1	918.4
Assets	941.9	1169.8	1610.1	1960.3	2020.6	2080.2






Particulars (Rs. Cr)	FY19	FY20	FY21	FY22	FY23	H1-FY24
Profit before tax	336.15	533.24	571.39	222.84	189.49	112.63
Adjustments for: Non Cash Items / Other Investment or Financial Items	82.35	51.93	27.15	33.12	44.42	29.60
Operating profit before working capital changes	418.50	585.17	598.54	255.96	233.91	142.23
Changes in working capital	-77.64	2.78	-76.51	-102.34	-63.67	49.09
Cash generated from Operations	340.86	587.95	522.03	153.62	170.24	191.32
Income tax paid(net)	-67.69	-117.15	-142.25	-62.58	-47.10	-31.00
Net cash flow from operating activities	273.17	470.80	379.78	91.04	123.14	160.32
Net cash flow from investing activities	-63.04	-184.23	-317.25	-120.62	-119.19	-129.07
Net cash from financing activities	-197.46	-271.89	-58.28	-1.64	-4.11	-29.14
Net Increase/Decrease in Cash and Cash equivalents	12.67	14.68	4.25	-31.22	-0.16	2.11
Cash & Cash equivalents at the beginning of the period	0.74	13.41	28.09	32.34	1.12	0.96
Cash & Cash equivalents at the end of the period	13.41	28.09	32.34	1.12	0.96	3.07




5-years Performance

IOL IOL Chemicals And Pharmaceuticals Limited



Diversified revenue base








* Amt in Rs.crore

COMPANY OVERVIEW

The Journey

IOL Chemicals And Pharmaceuticals Limited



Core management team

Varinder Gupta (Managing Director)

 Wide and rich experience of more than 35 years in the chemical & fertilizer industry and along with a comprehensive approach and strong Pharma API industry oversight has paved a way for innovation and excellence



Abhiraj Gupta (Executive Director*)

• Possesses requisite qualification and experience in the Company's business. He oversees the nonibuprofen API and chemical business, R&D, regulatory, digital marketing, and strategic decisions. The non-ibuprofen API business is doing good and meeting its targets under his leadership.

Vikas Vij (Chief Executive Officer*)

- Dynamic career spanning over 30 years showing year-on-year success in achieving profitability and business growth for various companies like Sun Pharma, Ranbaxy, Cipla leading API segment and Access Business Unit among others
- Has handled leadership roles across Pharma Value chain and Speciality Chemicals and achieved multi-million dollar sales target



 Academically equipped with knowledge and possesses organizational capacity. He has worked in strategic department of the Company and played a main role in guiding Chemical and Pharmaceutical business of the company. He has been vital to the functioning of the company over the last 7 years

Kushal Kumar Rana (Director - Works)

- Bachelor's in Chemistry, Physics, Math and Master's degree in Chemistry
- Over 30 years in the pharmaceutical industry in companies like Morepen Laboratories, Chemiplast Industries
- His expertise lies in looking after quality assurance, quality control & corporate regulatory affairs



Board of Directors



Rajender Mohan Malla

(Chairman and Independent Director)

- With four decades of experience held top and significant decision-making positions in Banks, Financial Institutions & NBFCs
- In his most recent executive roles, he was MD & CEO of PTC India Financial Services Limited (PFS), and prior to that CMD of IDBI

Dr. Sandhya Mehta

(Independent Director)

- Dr. Sandhya is working as the principal of Guru Nanak Institute of Management & technology, Ludhiana and has vast 22 year experience to her credit
- She has published seven books in addition to numerous papers published in reputed National & international Journals



- Over 35 year's experience of banking and financial services
- Most recently he was General Manager of Punjab National Bank and headed entire operations of bank in State of Punjab from 2010 to 2015

Sharad Tyagi (Independent Director)

- Over 35 years of intrapreneurship in India and international markets in diverse industries including pharmaceuticals, OTC, automotive catalysts and specialty chemicals
- Most recently until December 2020, he was the Managing Director for Boehringer Ingelheim (BI) (2009-2020), India

Certifications and Accreditations

- IOL Chemicals And Pharmaceuticals Limited



BUSINESS OVERVIEW



IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen having a capacity of 12000+ MT

- Dedicated USFDA approved facilities for Ibuprofen
- Among the largest producer of Metformin in India
- EUGMP Certification from National Institute of Pharmacy and Nutrition, Hungary for 12 APIs.
- Received approval from Korean FDA for 2 products and 6 products from Russian regulatory Authorities
- Filed 12 DMFs with USFDA & 5 CEP with EDQM.

Product Portfolio							
Existing Porffolio							
Ibuprofen	Clopidogrel	Losartan Potassium					
Ibuprofen Lysinate	Pantoprazole Sodium	Levetiracetam					
Ibuprofen Sodium	Fenofibrate	Paracetamol					
Dex-Ibuprofen	Gabapentin						
Metformin HCL	Lamotrigine						


Product application across various therapeutic areas



IOL Chemicals And Pharmaceuticals Limited

IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 TPA Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 1,00,000 TPA

- India's second largest manufacturer for Iso Butyl Benzene (IBB) with ~30% global share
- Received REACH Certificate for ethyl acetate and is exported to over 40 countries worldwide
- Asia's first continuous dual technology (green chemistry) plant for MCA and Acetyl Chloride





Manufacturing facilities











API manufactured in batch manner and intermediates & Specialty chemicals in continuous product delivery manner based on DCS technology

Manufacturing facilities involves -Reactions, Filteration, Centrifugation, Drying, Blending & Sieving, Micronization operation

Dedicated and multiproduct blocks involved in manufacturing of APIs

Four stage treatment zero discharge ETP, solvent recovery plants & EHS cell as a part of the facility

Research & Development

Facility is coupled with ISO class-8 HVAC

system, PSA Nitrogen & Purified water along with 127 MTPH steam generation capacity with multiple boilers

Dedicated decentralized utilities from -20 to 275 deg.C temp and dedicated co-generation plant of 17MW

110 Highly skilled members



Working on generic molecules with latest equipment & techniques for process development

DSIR approved facility for research & development



In-house development of multi step products

22



Environment


- Committed to ensure that our operations have minimal impact on the environment
- Constantly monitoring environmental footprints and implementing relevant initiatives.
- We have installed a Continuous Air Quality Monitoring System (CAAQMS) to monitor real-time concentrations of all key pollutants in ambient air.
 - Governance

We prioritize strong and effective corporate governance to ensure the best interests of all our stakeholders.

Social

- Committed towards making a difference in the lives of communities surrounding our operations through our CSR efforts
- We strive to create sustainable and meaningful change through our philanthropic efforts, reflecting our core values and commitment to social responsibility.

- Our continuous efforts have resulted in a 4.58% reduction in Scope-01 greenhouse gas (GHG) emissions during FY 2022-23.
- Our targets include a reduction in Scope-01 emissions by 45.21% and 100% reduction in Scope-02 emissions by 2035, based on the baseline emissions of FY 2021-22



INDUSTRY OVERVIEW

Pharmaceuticals - Emerging strongly out of pandemic




Indian API Market

World Pharmaceutical Industry




- Active Pharmaceutical Ingredient (or API) is a crucial segment of the pharma industry, contributing to around 35% of the market
- India is the 3rd largest producer of API accounting for an 8% share of the Global API Industry.
- About 500+ different APIs are manufactured in India, and it contributes 57% of APIs to prequalified list of the WHO.
- Data from the Pharmaceutical Exports Promotion Council (Pharmexcil) shows India imported \$3.18 billion worth of APIs and intermediates from China in 2022-23, up 1.74% from previous year.
- In 2021-22, India had imported \$3.12 billion worth of APIs and intermediates from China, which was up 19.5% from 2020-21.

Specialty Chemicals - an era of sustained robust growth



- The sector is projected to grow at 11-12% during 2021-27 and 7-10% during 2027-40 tripling its global market share by 2040.
- Specialty chemicals is expected to be a net exporter. By 2040, its net exports are expected to rise by around ten times, from about USD 2 billion in 2021 to USD 21 billion
- India has cost advantage in production of Iso-Butyl Benzene (IBB) compared to China (15% lower) and Germany (35% lower) commanding two-third of the global market

Factors driving growth of specialty chemicals in India



Indian Specialty Chemical Industry

Year	Chemical	Specialty Chemicals	Growth
2021	US\$170-180 Billion	US\$32 Billion	9-10%
2040	US\$ 850-1000 Billion	US\$140-190 Billion	11.5% (2021-27) 7-9.5% (2027-40)

Source: McKinsey - India: The Next Chemicals Manufacturing Hub, March 2023






26




WAY FORWARD

Charting a path to success

IOL Chemicals And Pharmaceuticals Limited



Expanding the non-Ibuprofen business



Thank You

Company :

Investor Relations Advisors :

IOL Chemicals & Pharmaceuticals Ltd.

Mr. Pardeep Kumar Khanna, CFO pardeepkhanna@iolcp.com

www.iolcp.com

THIRD DOLLARS

Adfactorspr Pvt. Ltd.

Darshan Mankad darshan.mankad@adfactorspr.com

Hanishi Shah hanishi.shah@adfactorspr.com

www.adfactorspr.com